The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now-Reference-Cited by-同舟云学术

The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now

Published:2017-05 Issue: Volume:113 Page:52-62
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Juárez-Salcedo Luis Miguel,Sandoval-Sus Jose,Sokol Lubomir,Chavez Julio C.,Dalia Samir

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference96 articles.

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;Alizadeh;Nature,2000

2. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells;Andorsky;Clin. Cancer Res.,2011

3. Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and FcεRI-signaling;Annenkov,2016

4. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome;Ansell;J. Clin. Oncol.,2001

5. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma;Ansell;Clin. Cancer Res.,2009

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma by diffusion and perfusion MRI: a preliminary study;BMC Medical Imaging;2024-08-26

2. Primary Renal Lymphoma: A Single-Center Study of 14 Cases;2024-08-09

3. Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas;Med;2024-06

4. Immunotherapy for diffuse large B-cell lymphoma: current use of immune checkpoint inhibitors therapy;AIMS Medical Science;2023

5. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma;Cancer Letters;2022-01